This webinar has been organised and funded by GSK UK. See bottom of page for full disclaimer.
*This GSK webinar contains promotional content
Incruse▼Ellipta (umeclidinium bromide): prescribing information
Anoro▼Ellipta (umeclidinium/vilanterol): prescribing information
Relvar Ellipta (fluticasone furoate/vilanterol): prescribing information
Trelegy▼Ellipta (fluticasone furoate/umeclidinium/vilanterol): prescribing information
Register now to GSKpro to access future webinars with medical experts and more.
Watch presentation from expert speakers:
Practice Nurse specialising in respiratory care
Dr Jennifer Quint
Consultant Respiratory Physician
Dr Sue Collier
UK National Physician Lead, GSK Respiratory
Learning objectives of this webinar:
- Discussion of tools to support the confirmation of COPD diagnosis
- Review the impact of symptoms and exacerbations on patients with COPD
- Explore the role of LAMA/LABA and ICS/LABA/LAMA maintenance medication in the treatment of COPD through problem-based case studies.
COPD=chronic obstructive pulmonary disease; ICS=inhaled corticosteroids; LABA=long-acting beta agonist; LAMA=long-acting muscarinic antagonist.
This webinar has been organised and funded by GSK UK. GSK UK has carried out full medical approval on all material to ensure compliance with regulations. Guidelines has had no involvement in the development of this webinar. The views and opinions of the speakers are not necessarily those of Guidelines, its publisher, advisers, or advertisers.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
Date of preparation: April 2020